Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings

American Journal of Clinical Pathology

Volumn 127, Issue 2, 2007, Pages 295-301

  Yoder, Brian J ^a,c   Skacel, Marek ^a   Hedgepeth, Ryan ^a   Babineau, Denise ^a,b   Ulchaker, James C ^a   Liou, Louis S ^a,d   Brainard, Jennifer A ^a   Biscotti, Charles V ^a   Jones, J Stephen ^a   Tubbs, Raymond R ^a,e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticipatory positive findings; Urothelial carcinoma; UroVysion multicolor FISH

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTITARGET FLUORESCENCE IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINE CYTOLOGY; UROGENITAL TRACT TUMOR; UROTHELIAL CARCINOMA; BLADDER TUMOR; CYSTOSCOPY; CYTODIAGNOSIS; CYTOLOGY; FOLLOW UP; MIDDLE AGED; TUMOR RECURRENCE; URINE;

CYSTOSCOPY; CYTODIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; URINE;

EID: 33847024987     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/ADJL7E810U1H42BJ     Document Type: Article

References (23)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol. 1998;22:1435-1448.
3. Knowles MA. Molecular genetics of bladder cancer: pathways of development and progression. Cancer Surv. 1998;31:49-76.
4. Canfield SE, Dinney CP, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 2003;30:791-802.
5. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61:190-118.
6. Halling KC, King W, Sokolova IA, et al. A comparison of BTA STAT, hemoglobin dipstick, telomerase, and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167:2001-2006.
7. Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol. 1993;11:145-153.
8. Tsai YC, Nichols PW, Hiti AL, et al. Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Res. 1990;50:44-47.
9. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors: cytogenetics and molecular genetics of bladder cancer. J Urol. 1994;151:545-560.
10. Skacel M, Tsiftsakis EK, Pettay JD, et al. Validation of a multicolor fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival thin-layer, liquid-based cytology slides. Anal Quant Cytol Histol. 2001;23:381-387.
11. Halling K, King W, Sokolova I, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;165:1768-1775.
12. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101-2105.
13. Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79-86.
14. Skacel M, Pettay JD, Liou LA, et al. Multicolor fluorescence in situ hybridization can reliably detect transitional cell carcinoma on ThinPrep slides in patients with atypical transitional cells non-diagnostic by urinary cytology [abstract]. Am J Clin Pathol. 2001;116:587.
15. Sarosdy AF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168:1950-1954.
16. Mostofi FK, Sobin LH, Torloni H. Histological Typing of Urinary Bladder Tumours. Geneva, Switzerland: World Health Organization; 1973. International Histological Classification of Tumours.
17. US Food and Drug Administration Center for Devices and Radiological Health. New device approval: UroVysion™ bladder cancer: P030052. January 24, 2005. Available at: http://www.fda.gov/cdrh/mda/docs/p030052.html. Accessed May 2005.
18. Sarosdy MF, Kahn PR, Ziffer MD, et al. Evaluation of a multi-target fluorescent in-situ hybridization (FISH) assay in the initial diagnosis of bladder cancer in patients with hematuria. J Urol. 2004;171(suppl):66.
19. Abbott. FDA approves first gene-based test, Urovysion, to aid initial diagnosis of bladder cancer in high risk hematuria [press release]. Available at http://www.vysis.com/FDAapproves UroVysiontoAidBladderCancerDiagnosis_56840. asp. Abbott Park, IL: Abbott; January 25, 2005. Accessed May 2005.
20. El-Rifai W, Kamel D, Larramendy ML, et al. DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer. Am J Pathol. 2000;156:871-878.
21. Gburek BM, Kollmorgen TA, Qian J, et al. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol. 1997;157:223-227.
22. Cianciulli A, Cosimelli M, Marzano R, et al. Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa. Cancer Genet Cytogenet. 2004;151:52-59.
23. Hughson MD, Dickman K, Bigler SA, et al. Clear-cell and papillary carcinoma of the kidney: an analysis of chromosomes 3, 7, and 17 abnormalities by microsatellite amplification, cytogenetics, and fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998;106:93-104.